Evidence for effects of older glucose-lowering agents on CV risk

Slides (curriculum) - Sep. 5, 2015

A slide lecture program on glucose lowering agents on CV risk, like: metformin, sulphonylureas, TZDs, and a rationale for FDA guidance.

Developed and provided by the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS), an initiative from Boehringer Ingelheim & Lilly and published as an educational service with permission at PACE-CME